Semaglutide injections reversed some cases of MASH liver disease in clinical trials, reducing inflammation in 62.9% of ...

A phase 3 trial shows that once-weekly semaglutide significantly improves liver histology in patients with metabolic ...

The US FDA has accepted Novo Nordisk’s new drug application (NDA) submission for the 25 mg oral formulation of Wegovy ...

Of the total ER visits, nearly 70% involved GI issues, 15% of which led to hospitalization, according to a new study.

Plainsboro, New Jersey Monday, May 5, 2025, 14:00 Hrs [IST] ...

Semaglutide and similar GLP-1 drugs are poised to become frontline treatments for a severe form of liver disease.

A new study analyzed how often people develop severe side effects after taking semaglutide — known by brand names Ozempic and ...

Interim results from the Phase III ESSENCE trial published in The New England Journal of Medicine show once-weekly ...

Once-weekly semaglutide 2.4 mg significantly reduced steatohepatitis and liver fibrosis symptoms among adults with metabolic ...

Nearly twice as many people taking semaglutide stopped their fatty liver disease without further scarring of the organ, ...

Ebn Sina Medical, a subsidiary of Aamal Company QPSC and a leading supplier of pharmaceutical, and Novo Nordisk, th ...